Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t understand any of this anymore.
Looks like they will be doing yet another RS after all!!! This really hurts…
Any chance they do another reverse split at this point in your opinion?
lol. That’s a good one!!! Keep them coming…it’s entertaining:)
lol. That’s a good one!!! Keep them coming…it’s entertaining:)
Exactly. And unless I missed it, there were no trades between roughly 2,75$ and 4,25$ !! Why this gap?
I get that also. But the IPO was around 4,25$ … am I right?
I thought about that Wahoo, but it’s unlikely. The price held for a while after the split, then one day to the next it dropped like from 10$ to 2.50$ with huge volume ( almost a third of the float was trading). I understand people would have enough and sell at a loss, but to have so many shares trading at such a substantial discount is fishy. There’s gotta be some other explanation.
Technical question ( no pumping or bashing ):
If the offering price was I believe 4,25$ , who is trading at these levels? How come there are people selling at these levels? ( it’s at 0,01 $ pre split !!). For anyone to sell here would mean they probably bought below 0,01 pre split! Also who can explain the sudden drop of over 80% ?
Again, no pumping or bashing please.
Question to the board:
When can Aegis start buying shares for its customers? Not sure if they’ve already started. In my opinion, the SP is being held back for this reason.
Any educated answer would be appreciated.
11
Crich, David (replaced Pegan internally as PI) In vivo efficacy and toxicology of SARS-PLpro Leads Sunshine Biopharma 2/1/2021 1/31/2022
As per above cut and paste, the end date of the allocated budget of 259,805$ is Jan 31,2022.
I’ve mentioned my thoughts before, and I’d like to post them again; feel free to comment:
• The company’s attempt to uplist a few months ago got turned down. But now, they are really going all in, and have applied to NASDAQ with the help of an IB. Ask yourself: why in the world would Sunshine even think about Nasdaq if they had failed in their preliminary trials ( mice trials for Covid or Adva … either/or ). Why in the world would Aegis Capital even consider helping out Sunshine if they hadn’t done their DD by verifying all their recent studies/results??
Applying to Nasdaq gives me enormous confidence that results are very positive, and that good news will start to flow in soon. If results were not successful, it would be like someone going into a major final exam without studying , guaranteed to fail!!
The writing is on the wall IMO.
Recent downtrend is normal, due to lack of communication from the company. This lack could be simply because they are not allowed to give details just yet.
Obviously, Aegis had a plan. Once we uplist thanks to a RS, News should start to flow to maintain the needed SP. if not, Aegis would have failed, which will not be good for their reputation.
Obviously, there are no guarantees, as this is the stock market, but I have a good feeling about the process.
Nothing but buy orders since 10 AM.
Does anyone know when the “quiet period” technically ends?
Another thing:
What makes you think there will only be one pill? Merck might make one, so might Pfizer.
But for a simple thing like a headache, you have Tylenol, Advil, eccedrin, etc.
I believe there will be more then one pill available.
On top of all this, we have the cancer treatment in the works!
Wake up.
Enough said.
If in doubt, think about this:
They started mice studies quite a while back, and have been working with UGA for months. If results were not almost guaranteed to be positive, why in the world would they even bother applying to Nasdaq ? To be the laughing stock of the investment community? Why in the world would Aegis Capital consider Sunshine ?
In my Opinion, this is ready to go. If you are waiting for an official PR to confirm all this, it is your choice, but you might as well forget these levels once the PR hits.
Just read, and re-read the last PR. If there is any truth to it, we are in for a life changing ride.
As a long time investor, I am more excited by the news then the actual SP increase believe it or not! This can be life changing:)
Message from Deborah from RB CAPITAL
$SBFM great buying opportunity today as I think this stock is undervalued. #curecancer #covidinhibitor #cancertreatment @BrettRosen325
$SBFM great buying opportunity today as I think this stock is undervalued. #curecancer #covidinhibitor #cancertreatment @BrettRosen325
— Deborah (@deborahrachelb) May 24, 2021
As per this article, we should see in 5 days if mice will resist or not...see the last paragraph:
The severe acute respiratory syndrome (SARS) outbreak at the end of 2002 was a global infectious disease epidemic. According to the World Health Organization (WHO), over 8,000 people were infected and over 700 died worldwide. The culprit causing the epidemic was the SARS coronavirus (SARS-CoV), which is named for the coronal or crown shape on the outer membrane of the virus.
At the end of 2019, several unidentified pneumonia cases were found in Wuhan, China, which rapidly spread to all parts of the country and multiple countries around the world. These cases and many others that continue to be reported are due to a newly identified coronavirus, SARS-CoV-2, that is currently under intense scientific scrutiny.
Both the number of patients infected and those that have died from the current coronavirus epidemic now exceed the total of those from the SARS outbreak in 2002. The pathogens that caused both outbreaks belong to the Coronaviridae family. The World Health Organization has recently named the current disease outbreak COVID-19. Currently, there are no effective vaccines or treatments available for this virus, though a novel coronavirus vaccine (jointly designed and developed by the Chinese Center for Disease Control and Prevention, Tongji University School of Clinical Medicine and Stemirna Therapeutics) is expected to enter clinical trials in April.
Mouse models play a critical role in both vaccine and drug development. Studies have shown that SARS-CoV enters the human body by binding to human angiotensin-converting enzyme 2 (ACE2). However, due to structural differences in mouse ACE2 compared to human ACE2 proteins, the SARS coronaviruses exhibit poor tropism characteristics for mouse tissues and are inefficient at infecting mice. As a result of this poor viral tissue tropism in mice, commonly used wild-type mouse strains are not optimal for studying infections of the newly discovered coronavirus. Fortunately, a transgenic model is now available to fill the unmet need for an in vivo experimental platform for COVID-19 research.
Introducing the K18-hACE2 transgenic mouse for coronavirus research
In 2007, Dr. Paul McCray, et al from the University of Iowa published a study in which they introduced a vector carrying a human ACE2-coding sequence into wild-type mice and subsequently developed a successful hACE2 transgenic mouse strain. ACE2 expression, which is regulated by the human cytokeratin 18 (K18) promoter in epithelial cells, was observed in the initially infected airway epithelial cells. Studies showed that the K18-hACE2 transgenic mouse infected with a human SARS-CoV strain via intranasal inoculation would not survive.
The infection would begin in the airway epithelium, spread to the alveoli and finally out of the lungs to the brain. The infection causes infiltration of macrophages and lymphocytes in the lungs and up-regulation of pro-inflammatory cytokines and chemokines in the lungs and brain. Three to five days following infection, K18-hACE2 mice began to lose weight and become lethargic with labored breathing. All died within seven days. These observations support that transgene expression of hACE2 in epithelial cells can convert moderate SARS-CoV infection into a fatal disease.
The poster says he spoke to Camille for 45 minutes... it’s just reassuring to hear the comments from mr Sebaaly, that’s all...
Hi guys, check out this post from stocktwits:
https://stocktwits.com/Izzy12345/message/301053505
Definitely painful.
Needing concrete good news here.
Here’s my question to Brett Rosen, and his response:
Hi Brett, hope you are well!
I’d like your honest opinion on SBFM; what are your thoughts for the short term ( 1 month ) and long term. I’ve been a shareholder of Sunshine Bio since 2013!!
Thanks in advance!
I love the company. I have $3m invested with a $0.30 to $0.60 cost basis. I believe they hit $1 before Q4 2021.
Thank you very much for your long term support of $sbfm.
Heck, if it goes to 2$ I’ll invite you all to my house!!!
Look at the date in the « international application status » :
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005060344&tab=PCTDOCUMENTS
I hope you’re right, but what makes you say that?
Hi guys, listen to the last 4 minutes of this video, talking about SBFM...
I don’t think this is a race against that other company or anyone for that matter. There could be two, three companies who will come up with a pill, and they’ll all be successful. Look at the companies that came up with the vaccine ( Moderna, Phizer, etc).
We are definitely on the right track; for years, financing was our biggest issue, and now that is taken care of.
2 things that we all need to remember:
1) our CEO got shares thanks to his work on COVID ( molecules, etc). He is ale to redeem once they got 0.10, but I doubt he will, as he is a hands on scientist ( second to none by the way), and knows where this is going.
2) Our financing partners RB want this to go as high as possible; 0.30 is the next logical step that Sunshine I needs to get to.
All this being said, once the PR’s start coming in, we will not have time to sell our shares... that’s how fast this will move from these levels to dollar land.
Please mark my words.
All imho.
Question:
I own shares of Aphria on the TSX in Canadian dollars. Can anyone tell me how my shares will be transferred once the merger happens?
The conversion rate agreed upon is obviously for Aphria shares that trade on Nasdaq.
Would be kind of unfair if they kept the same conversion rate; it will also be unfair for investors with the Canadian Aphria shares if they were to convert them to US$ to then own TLRY shares with the converted dollar amount ( as we would lose money on the rate of exchange)
Anyone with an educated guess?
Thanks in advance
Remember:
There isn’t just one vaccine that’s going to be approved; there’s Moderna, Pfizer, etc. Just like there will not only be one pill. We have many pills that treat headaches for example, and they all work and are all profitable!
I sent an email yesterday to Dr Susannah Gal, who had worked on Adva-27 years ago; she replied this morning. Here’s my email to her, and her quick response:
Hello Dr Gal,
I hope you are well. My name is Mardig. I was doing some research and came across your name regarding a cancer drug that you had done some laboratory work on some years ago.
Can you perhaps provide me with your thoughts ( if you remember) about your findings? Was the drug a promising one?
Many thanks in advance.
Kindest Regards,
...
Dear Mardig;
Thank you for writing.
The work I did on the drug was only with cancer cells in culture. This work did look very promising though in that limited context, i.e. I do not know how well it works in tissues or whole animals.
I have not kept up that work so do not know of further advances.
Dr. Susannah Gal
Susannah Gal, PhD
Professor of Biology
Penn State Harrisburg
175 Science and Technology Building
Stop thinking that whenever there is news about a big pharmacy company finding a valid vaccine means the end of the road for Sunshine. As Mr Afeyan ( founder and CEO of Moderna) himself announced a few months ago, this is not a race to find THE ONE AND ONLY CURE. There will not be only one vaccine. Many different vaccines/treatments will be needed.
What we have is unique. Time will tell. Stay tuned:)
MM games: my order at 0.0185 no getting filled, yet trades are in at 0.0179...
The part I find very interesting on the 8k:
“The Agreement grants us an exclusive worldwide license for all of the intellectual property developed by UGA, whether alone or jointly with us.”
... This is HUGE.
Make no mistake people...
It’s just a matter of time. Could be hours, days, or a few weeks. But the stock price WILL go up. When it does, it will move up aggressively.
Please remember this post.
All imo.
Question to the board:
How can you tell what the float is, and how much the MM’s have control ( how much they have)?
Question:
Our company filed a patent request on intellectual property. What does this have to do with the FDA?